Home/Pipeline/AKT1 Inhibitor Program

AKT1 Inhibitor Program

Oncology

DiscoveryActive

Key Facts

Indication

Oncology

Phase

Discovery

Status

Active

Company

Micar Innovation

About Micar Innovation

Micar Innovation is a private, pre-revenue biotech company providing AI-powered computational drug discovery services and developing its own internal pipeline. Its core technology platform integrates advanced molecular modeling, dynamics, and free energy calculations to de-risk and accelerate early-stage drug discovery, claiming to reduce the timeline for entire discovery processes to 2-8 weeks. The company targets orphan GPCRs, understudied proteins, and rare diseases, and has demonstrated its capabilities through published research on SARS-CoV-2 variants and partnerships for medicinal cosmetics development.

View full company profile

Therapeutic Areas

Rare Diseases Metabolic Disorders Oncology Neurological Disorders Infectious Diseases Cardiovascular

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active